论文部分内容阅读
目的:观察丹红注射液联合低分子肝素钙治疗不稳定型心绞痛的临床疗效及安全性。方法:94例不稳定型心绞痛患者,随机分成对照组46例和治疗组48例。对照组在常规口服硝酸异山梨酯、肠溶阿司匹林、美托洛尔、培哚普利等基础上加用低分子肝素钙4 100 iu,ih,qd;治疗组在上述基础上再加用丹红注射液30 ml于5%葡萄糖注射液250 ml中ivd,qd,7d 1个疗程,比较两组心绞痛等临床症状、心电图变化及血液流变学变化指标。结果:治疗组与对照组临床症状总有效率和心电图总有效率分别为94.0%(76.0%)和81.2%(66.0%),差异有统计学意义(P<0.05),治疗组治疗后血浆黏度、血小板聚集率和红细胞平均体积均显著降低,有统计学差异(P<0.05)。临床应用中未见明显的不良反应,患者肝、肾功能等亦无明显改变。结论:不稳定型心绞痛在常规治疗基础上合用低分子肝素钙和丹红注射液治疗临床疗效显著,不良反应小。
Objective: To observe the clinical efficacy and safety of Danhong injection and low molecular weight heparin in the treatment of unstable angina pectoris. Methods: 94 patients with unstable angina were randomly divided into control group (n = 46) and treatment group (n = 48). Control group in the conventional oral isosorbide dinitrate, enteric-coated aspirin, metoprolol, perindopril and other based on the addition of low molecular weight heparin calcium 4 100 iu, ih, qd; the treatment group on the basis of the above with Dan Red injection 30 ml in 5% glucose injection 250 ml ivd, qd, 7d a course of treatment, angina pectoris and other clinical symptoms, ECG changes and changes in hemorheology indicators. Results: The total effective rate of clinical symptoms and the total effective rate of electrocardiogram in treatment group and control group were 94.0% (76.0%) and 81.2% (66.0%) respectively, the difference was statistically significant (P <0.05). The plasma viscosity , Platelet aggregation rate and the average volume of red blood cells were significantly lower, with statistical differences (P <0.05). No significant adverse reactions in clinical application, liver function, renal function, no significant change. Conclusion: Unstable angina pectoris combined with low molecular weight heparin calcium and Danhong injection on the basis of routine treatment has significant clinical effect and small adverse reaction.